Genomics

Human Identification Market Report 2022: Rising Adoption of Forensic Applications Bolsters Growth

Retrieved on: 
Thursday, March 23, 2023
Molecular biology, Component, DNA, Hair, Laboratory, QIAGEN, Ear, ARUP Laboratories, Chromatin, NGS, ICMP, Semen, Intelligence, Research, Genomics, RNA, Proteomics, Qiagen, Cloud computing, ARUP, Investment, Application, Blood, Crime, Growth, Skin, Video game

The global human identification market is anticipated to observe impressive growth during the forecast period, 2023-2027.

Key Points: 
  • The global human identification market is anticipated to observe impressive growth during the forecast period, 2023-2027.
  • Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are augmenting the growth of the market.
  • The increasing use of forensic applications is fueling the growth of the global human identification market.
  • In this report, global human identification market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

OSF HealthCare and Illinois State launch Connected Communities Initiative (CCI) to expand research and develop solutions to transform health care

Retrieved on: 
Thursday, March 23, 2023
Civic, Illinois State University College of Arts and Sciences, Blockchain, Bloomington–Normal, Bradley University, STEAM, Partnership, University of Illinois Chicago, Civic engagement, OSF HealthCare, University, Education, Vaccination, Bed, Nursing, CCI, Illinois State University, Teaching, Sister, Interprofessional education, Research, Postgraduate education, Genomics, Mentorship, University of Illinois Urbana-Champaign, Person, IIN, Organization, Student, Hospital, Beverley Vozenilek, Digital health, MD, Patient, OSF, Missionary, Economic development, Learning, Medicine, Ideation, Faculty, Growth, ISU, Third order, Health, Data science, Pharmaceutical industry, Doctor of Philosophy

BLOOMINGTON, Ill., March 23, 2023 /PRNewswire/ -- A newly formalized partnership between Illinois State University and OSF HealthCare will foster research, innovation, and economic development across Illinois.

Key Points: 
  • BLOOMINGTON, Ill., March 23, 2023 /PRNewswire/ -- A newly formalized partnership between Illinois State University and OSF HealthCare will foster research, innovation, and economic development across Illinois.
  • Illinois State and OSF HealthCare are lead hub members of the Illinois Innovation Network (IIN).
  • OSF Healthcare and Illinois State University have a tradition of collaboration on research, including a recent project to improve low childhood vaccination rates.
  • OSF HealthCare, through OSF Home Care Services, operates an extensive network of home health and hospice services.

David Stemler joins CultHealth as Chief Creative Officer

Retrieved on: 
Thursday, March 23, 2023
Acceleration, Creativity, HuffPost, Genomics, Marketing, Creative industries, Indegene, Bloc

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- CultHealth, an Indegene company, has appointed David Stemler as Chief Creative Officer.

Key Points: 
  • NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- CultHealth, an Indegene company, has appointed David Stemler as Chief Creative Officer.
  • David will help CultHealth define and shape its creative strategy and direction, and deliver engaging brand campaigns that aim to generate real business outcomes for clients.
  • “David is a creative genius, and I am thrilled to welcome him into the CultHealth family at an exciting time in our growth journey.
  • We will double down on delivering more inspiring and engaging client campaigns.”
    “There is a massive opportunity to help life sciences brands reimagine marketing and consumer engagement,” said David Stemler, Chief Creative Officer, CultHealth.

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 22, 2023
PRISM, 50/50 (2011 film), Takeda, C9orf72, MBA, Cerebrospinal fluid, Protein, MD, Observation, RNA interference, DSM-IV codes, Disease, Duchenne muscular dystrophy, Therapy, Genetics, Aimer, Pharmacokinetics, Mutation, Research, Gene expression, Small RNA, AATD, N-Acetylgalactosamine, Episcopal conference, Muscular Dystrophy Association, Sirna Therapeutics, Liver, MDA, IND, Conference, Safety, GSK, SERPINA1, Messenger, Webcast, APP, RNA editing, HD, ICV, Central nervous system, Q&A, Genomics, RNA, CNS, CTAS, DMD, Mouse, Pharmaceutical industry, Broadcasting, Vaccine, Cryptocurrency, Video game, Wave

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  • Research and development expenses were $31.1 million in the fourth quarter of 2022 as compared to $25.8 million in the same period in 2021.
  • As of December 31, 2022, Wave had $88.5 million in cash and cash equivalents, as compared to $150.6 million as of December 31, 2021.
  • ET to discuss the fourth quarter and full year 2022 financial results and provide a business update.

Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females

Retrieved on: 
Wednesday, March 22, 2023
Vagina, Pregnancy, FISH, CMA, Augusta University, Genomics, Parent, KT, SVS, Mosaic, Research, Doctor of Philosophy, Uterus, Disorder, SV, Karyotype, CNV, Chromosomal translocation, Patient, SNP, Fertility, OGM, Gene, Syndrome, PCR, Trisomy, Female, Disease, Pharmaceutical industry, Microscope, Birth control, Medical imaging, Vaccine, Agriculture, MRKH

MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy.

Key Points: 
  • MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy.
  • Molecular diagnosis is helpful in determining the best treatment for MRKH, but because genetic causes are largely unknown, research into this prevalent class of disorders is key to enabling effective therapies.
  • In this study, researchers used OGM to analyze MRKH samples to detect a variety of SVs that may be relevant to MRKH’s genetic etiology in a single assay.
  • We believe the authors’ findings that indicate mosaicism, including for a trisomy 12, could be involved in the pathogenesis of MRKH were particularly significant,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases

Retrieved on: 
Wednesday, March 22, 2023
Partnership, Natural history, Genetics, Research, Genomics, Disorder, Patient, SAN, Drug discovery, Rare, NYSE, Disease, Pharmaceutical industry, Invitae

SAN FRANCISCO, March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company, a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and clinical data from millions of patients and Deerfield's broad drug discovery and development expertise.

Key Points: 
  • Through this partnership, we intend to serve millions of families affected by rare diseases with high unmet needs," said Farid Vij, general manager of patient network and data at Invitae.
  • "Despite significant research efforts, there are thousands of rare diseases without a line of sight toward a viable therapeutic intervention," said Matt Nelson, head of genetics and genomics at Deerfield Management.
  • Invitae and Deerfield aim to address notable research gaps by drawing insights from Invitae's data platform, which includes sizable cohorts of rare disease patients.
  • With these data and analytics expertise, together Invitae and Deerfield will be well-suited to uncover insights needed to discover and validate novel rare disease targets.

Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 21, 2023
Molecular biology, GMP, SAB, Exercise, Good, Business development, Partnership, Drug development, Biochemistry, Marketing, Biotechnology, Cancer, Quality of life, Coronavirus Scientific Advisory Board, Intelligence, Wall Street, MBA, Research, Genomics, Cell, CLIA, Acquisition, Patient, Good manufacturing practice, CBO, Machine learning, ACE, Corporation, Drug discovery, Artificial intelligence, Growth, Piper, Foundation Medicine, DLA Piper, Pharmaceutical industry, Cryptocurrency, Medical imaging, Management, Security (finance), IP

Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.

Key Points: 
  • Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.
  • Appointed Pamela Bush, Ph.D., MBA, as Chief Business Officer (CBO) to lead the company’s business development, partnering and growth initiatives.
  • The consolidated reportable segments of Predictive Oncology recorded revenue of $1,505,459 in 2022, compared to $1,420,680 in 2021.
  • We incurred net losses of $25,737,634 and $19,657,174 for the years ended December 31, 2022, and December 31, 2021, respectively.

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

Retrieved on: 
Tuesday, March 21, 2023
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Xchange, Genomics, American Chemical Society, Machine learning, Science History Institute, Artificial intelligence, Pharmaceutical industry, Lantern

ET.

Key Points: 
  • ET.
  • How Artificial Intelligence Is Changing Drug Discovery Webinar on Thursday, March 23 at 1:00 p.m.
  • ET.
  • ET.

NVIDIA Unveils Large Language Models and Generative AI Service to Advance Life Sciences R&D

Retrieved on: 
Tuesday, March 21, 2023
Cloud, Molecular biology, DNA, Drug development, Therapy, Meta, Health, Acceleration, Synthetic media, 3D, Deep learning, Enzyme, Web browser, Research, Medicine, Genomics, RNA, Orientation, Antibody, DeepMind, Protein, Chemistry, GTC, Patient, Nature, NVIDIA, Insilico Medicine, Inception, Drug discovery, Biology, AI, API, AlphaFold, Medical device, Pharmaceutical industry, Fine chemical, Amgen

Part of NVIDIA AI Foundations , the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery.

Key Points: 
  • Part of NVIDIA AI Foundations , the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery.
  • “The transformative power of generative AI holds enormous promise for the life science and pharmaceutical industries,” said Kimberly Powell, vice president of healthcare at NVIDIA.
  • Generative AI models can rapidly identify potential drug molecules — in some cases designing compounds or protein-based therapeutics from scratch.
  • The BioNeMo Service makes these generative AI models easily accessible through a browser-based interface for interactive inference and protein structure visualization.

Gencove Appoints Alex Dickinson to its Board of Directors

Retrieved on: 
Tuesday, March 21, 2023
Columbia University, DNA, Adelaide, University, Cisco, Genotyping, Infection, Cancer, Electrical engineering, MBA, Genomics, Doctor of Philosophy, Whole genome sequencing, Cloud computing, Patient, Medicine, Luxtera, Electricity, Genome, Management, Illumina

New York, March 21, 2023 (GLOBE NEWSWIRE) -- Gencove, pioneer of low-pass whole genome sequencing and analysis software, is pleased to announce the appointment of Dr. Alex Dickinson to its Board of Directors.

Key Points: 
  • New York, March 21, 2023 (GLOBE NEWSWIRE) -- Gencove, pioneer of low-pass whole genome sequencing and analysis software, is pleased to announce the appointment of Dr. Alex Dickinson to its Board of Directors.
  • He joins Joseph Pickrell and Tomaz Berisa, co-founders of Gencove, Sara Eshelman of Spero Ventures, and Larry Page of Lewis & Clark AgriFood on the Board.
  • “I’m very pleased to join the Gencove Board of Directors,” said Alex.
  • “This addition to the board signals our investment in expanding the commercial reach and maturity of Gencove.